1Taqwa Saoud Abdul-Aali, 2Ibrahim A. Altamemi, 3Osamah T. Muslim
1Department of Biology, College of Science, University of Al-Qadisiyah / Iraq
2DR. Prof. / department of microbiology / college of medicine / University of Al-Qadisiyah / Iraq.
3DR. Prof. / department of internal medicine / college of medicine / University of Al-Qadisiyah / Iraq.
1https://orcid.org/0000-0002-8501-7471,
2 https://orcid.org/0000-0002-4598-6251,
3https://orcid.org/0000-0003-1981-6715
DOI : https://doi.org/10.47191/ijmra/v6-i10-49Google Scholar Download Pdf
ABSTRACT:
Ulcerative colitis is common and complex conditions that are difficult to cure. MiRNAs are a class of small, non-coding, single-stranded RNA molecules which play a key role in autoimmune and inflammatory diseases especially in IBD. Despite the efficacy of biological treatment, a significant proportion of patients with IBD do not show an adequate response. For this reason it is crucial to identify biomarkers useful to predict clinical response. In present study, we aimed to evaluate the microRNA-155 (miR-155) and microRNA-223 (miR-223) as prognostic marker in disease response to therapy in patients with UC. This study included 80 patients with UC (40 patients who response to conventional treatment and 40 who resist and they are on biological treatment) and 40 healthy controls. Real-time polymerase chain reaction (RT-PCR) assay was performed for evaluation miRNA-155 and miRNA-223. According to the results of this study, There was significant variation in mean fold change of miR-155 among groups (p <0.001), the level was highest in patients on conventional treatment followed by patients on biological therapy and then by control group. With respect to miR-223, the difference in mean fold change was significant among study groups (p <0.001), the level was highest in patients on biological treatment followed control group and then by patients on conventional therapy. Receiver operator characteristic (ROC) curve analysis was carried, the cutoff value of miRNA-155 was ≤1.43 with 20 % sensitivity level, 95 % specificity level and 53.3% accuracy level. The cutoff vale of miRNA-223 was >4.51with 25 % sensitivity level, 92.5% specificity level and 59.1 % accuracy level. In conclusion, this study have evaluated the therapeutic response to corticosteroid, or IFX therapy and blood expression of miRNA by screening the responses to anti-TNF-α and conventional therapy, this study demonstrated that the level of miRNA-223 associated with the response to IFX which is highly increased in biological therapy (negative response) comparing to the conventional therapy (positive response) group after IFX therapy while the present study demonstrated that miRNA-155 fold change upregulated in patients with ulcerative colitis and on conventional therapy (positive response) in comparison with healthy control group.
REFERENCES:
1) Jiezhong Chen LV. Is miR-223 Upregulation in Inflammatory Bowel Diseases a Protective Response? Front Biosci - Elit. 2023;15(1).
2) Quaglio AEV, Santaella FJ, Rodrigues MAM, Sassaki LY, Di Stasi LC. MicroRNAs expression influence in ulcerative colitis and Crohn’s disease: A pilot study for the identification of diagnostic biomarkers. World J Gastroenterol. 2021;27(45):7801-7812. doi:10.3748/wjg.v27.i45.7801
3) Wang P, Chen Y, Zhang LM, Yuan SQ, Lu SA, Zhang YJ. Effect of MicroRNA145 on the multidrug resistance gene of ulcerative colitis in rats. Life Sci. 2021;278(January):119603. doi:10.1016/j.lfs.2021.119603
4) Yan X-Y, Yao J-P, Li Y-Q, et al. Global trends in research on miRNA–microbiome interaction from 2011 to 2021: A bibliometric analysis. Front Pharmacol. 2022;13(August):1-18. doi:10.3389/fphar.2022.974741
5) Yarani R, Shojaeian A, Palasca O, et al. Differentially Expressed miRNAs in Ulcerative Colitis and Crohn’s Disease. Front Immunol. 2022;13(June):1-21. doi:10.3389/fimmu.2022.865777
6) Guo J, Liao M, Wang J. TLR4 signaling in the development of colitis-associated cancer and its possible interplay with microRNA-155. Cell Commun Signal. 2021;19(1):1-22. doi:10.1186/s12964-021-00771-6
7) Zhang J, Wang C, Guo Z, Da B, Zhu W, Li Q. miR-223 improves intestinal inflammation through inhibiting the IL-6/STAT3 signaling pathway in dextran sodium sulfate-induced experimental colitis. Immunity, Inflamm Dis. 2021;9(1):319-327. doi:10.1002/iid3.395
8) Zhou J, Liu J, Gao Y, Shen L, Li S, Chen S. miRNA-Based Potential Biomarkers and New Molecular Insights in Ulcerative Colitis. Front Pharmacol. 2021;12(July):1-17. doi:10.3389/fphar.2021.707776
9) Zhu Y, Yang S, Zhao N, et al. CXCL8 chemokine in ulcerative colitis. Biomed Pharmacother. 2021;138(February):111427. doi:10.1016/j.biopha.2021.111427
10) Shimodaira Y, Watanabe K, Iijima K. Clinical course of ulcerative colitis associated with an age at diagnosis: A recent japanese database survey. Tohoku J Exp Med. 2021;255(1):33-39. doi:10.1620/tjem.255.33
11) Mak JWY, Lok Tung Ho C, Wong K, et al. Epidemiology and Natural History of Elderly-onset Inflammatory Bowel Disease: Results from a Territory-wide Hong Kong IBD Registry. J Crohn’s Colitis. 2021;15(3):401-408. doi:10.1093/ecco-jcc/jjaa181
12) Zammarchi I, Lanzarotto F, Cannatelli R, et al. Elderly-onset vs adult-onset ulcerative colitis: A different natural history? BMC Gastroenterol. 2020;20(1):4-11. doi:10.1186/s12876-020-01296-x
13) Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012;380(9853):1606-1619. doi:10.1016/S0140-6736(12)60150-0
14) Aggarwal A, Mehta S, Gupta D, et al. Clinical & immunological erythematosus patients characteristics in systemic lupus Maryam. J Dent Educ. 2012;76(11):1532-1539. doi:10.4103/ijmr.IJMR
15) Lungaro L, Costanzini A, Manza F, et al. Impact of Female Gender in Inflammatory Bowel Diseases: A Narrative Review. J Pers Med. 2023;13(2). doi:10.3390/jpm13020165
16) Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients with Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J Crohn’s Colitis. 2020;14(5):694-709. doi:10.1093/ecco-jcc/jjz195
17) Murthy SK, Greenberg GR, Croitoru K, Nguyen GC, Silverberg MS, Steinhart AH. Extent of early clinical response to infliximab predicts long-term treatment success in active ulcerative colitis. Inflamm Bowel Dis. 2015;21(9):2090-2096. doi:10.1097/MIB.0000000000000474
18) Nguyen NH, Kurnool S, Dulai PS, Boland BS, Sandborn WJ, Singh S. Short disease duration is associated with increased risk of treatment failure in biologic-Treated patients with ulcerative colitis. Inflamm Bowel Dis. 2020;26(9):1429-1435. doi:10.1093/ibd/izz276
19) Min M, Peng L, Yang Y, Guo M. MicroRNA-155 Is Involved in the Pathogenesis of Ulcerative Colitis by Targeting FOXO3a. Inflamm Bowel Dis. 2014;20(4):652-659. doi:10.1097/MIB.0000000000000009
20) Mahesh G, Biswas R. MicroRNA-155: A Master Regulator of Inflammation. J Interf CYTOKINE Res. 2019;39(6):321-330. doi:10.1089/jir.2018.0155
21) Xiao X, Mao X, Chen D, et al. miRNAs Can Affect Intestinal Epithelial Barrier in Inflammatory Bowel Disease. Front Immunol. 2022;13(April):1-13. doi:10.3389/fimmu.2022.868229
22) Malham M, James JP, Jakobsen C, et al. Mucosal microRNAs relate to age and severity of disease in ulcerative colitis. Aging (Albany NY). 2021;13(5):6359-6374. doi:10.18632/aging.202715
23) Pashangzadeh S, Motallebnezhad M, Vafashoar F, Khalvandi A. Implications the Role of miR-155 in the Pathogenesis of Autoimmune Diseases. Front Immunol. 2021;12(May):1-14. doi:10.3389/fimmu.2021.669382
24) Li T, Jia Y, Wang Q, Shao X, Zhang P, Lv R. Correlation between Tumor Necrosis Factor alpha mRNA and MicroRNA-155 Expression in Rat Models and Patients with Temporal Lobe Epilepsy. Brain Res. 2018;1700:56-65. doi:10.1016/j.brainres.2018.07.013
25) Yang Z Bin, Qiu LZ, Chen Q, Lin JD. Artesunate alleviates the inflammatory response of ulcerative colitis by regulating the expression of miR-155. Pharm Biol. 2021;59(1):97-105. doi:10.1080/13880209.2020.1867196
26) Schaefer JS, Attumi T, Opekun AR, et al. MicroRNA signatures differentiate Crohn’s disease from ulcerative colitis. BMC Immunol. 2015;16(1):1-13. doi:10.1186/s12865-015-0069-0
27) James JP, Riis LB, Malham M, Høgdall E, Langholz E, Nielsen BS. MicroRNA biomarkers in IBD-differential diagnosis and prediction of colitis-associated cancer. Int J Mol Sci. 2020;21(21):1-19. doi:10.3390/ijms21217893
28) Kim HY, Kwon HY, Ha Thi HT, et al. MicroRNA-132 and microRNA-223 control positive feedback circuit by regulating FOXO3a in inflammatory bowel disease. J Gastroenterol Hepatol. 2016;31(10):1727-1735. doi:10.1111/jgh.13321
29) Aggeletopoulou I, Mouzaki A, Thomopoulos K, Triantos C. miRNA Molecules—Late Breaking Treatment for Inflammatory Bowel Diseases? Int J Mol Sci. 2023;24(3). doi:10.3390/ijms24032233
30) Béres NJ, Szabó D, Kocsis D, et al. Role of Altered Expression of MIR-146a, MIR-155, and MIR-122 in Pediatric Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016;22(2):327-335. doi:10.1097/MIB.0000000000000687
31) Fujioka S, Nakamichi I, Esaki M, Asano K, Matsumoto T, Kitazono T. Serum microRNA levels in patients with Crohn’s disease during induction therapy by infliximab. J Gastroenterol Hepatol. 2014;29(6):1207-1214. doi:10.1111/jgh.12523
32) Lu P De, Zhao YH. Targeting NF-κB pathway for treating ulcerative colitis: Comprehensive regulatory characteristics of Chinese medicines. Chinese Med (United Kingdom). 2020;15(1):1-25. doi:10.1186/s13020-020-0296-z
33) Valmiki S, Ahuja V, Puri N, Paul J. miR-125b and miR-223 Contribute to Inflammation by Targeting the Key Molecules of NFκB Pathway. Front Med. 2020;6(January):1-14. doi:10.3389/fmed.2019.00313
34) Bank S, Andersen PS, Burisch J, et al. Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014;14(6):526-534. doi:10.1038/tpj.2014.19
35) Atreya I, Atreya R, Neurath MF. NF-κB in inflammatory bowel disease. J Intern Med. 2008;263(6):591-596. doi:10.1111/j.1365-2796.2008.01953.x
36) Fasseu M, Tréton X, Guichard C, et al. Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One. 2010;5(10). doi:10.1371/journal.pone.0013160
37) Dragoni G, Innocenti T, Galli A. Biomarkers of Inflammation in Inflammatory Bowel Disease: How Long before Abandoning Single-Marker Approaches? Dig Dis. 2021;39(3):190-203. doi:10.1159/000511641
38) Xu J, Xu HM, Yang MF, et al. New Insights Into the Epigenetic Regulation of Inflammatory Bowel Disease. Front Pharmacol. 2022;13(January):1-15. doi:10.3389/fphar.2022.813659
39) Dalal SR, Kwon JH. The role of microRNA in inflammatory bowel disease. Gastroenterol Hepatol. 2010;6(11):714-722.
40) Cui G, Fan Q, Li Z, Goll R, Florholmen J. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. EBioMedicine. 2021;66:103329. doi:10.1016/j.ebiom.2021.103329
Volume 06 Issue 10 October 2023
There is an Open Access article, distributed under the term of the Creative Commons Attribution – Non Commercial 4.0 International (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/), which permits remixing, adapting and building upon the work for non-commercial use, provided the original work is properly cited.
Our Services and Policies
Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected.
The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.
International Journal of Multidisciplinary Research and Analysis will publish 12 monthly online issues per year,IJMRA publishes articles as soon as the final copy-edited version is approved. IJMRA publishes articles and review papers of all subjects area.
Open access is a mechanism by which research outputs are distributed online, Hybrid open access journals, contain a mixture of open access articles and closed access articles.
International Journal of Multidisciplinary Research and Analysis initiate a call for research paper for Volume 07 Issue 05 (May 2024).
PUBLICATION DATES:
1) Last Date of Submission : 26 May 2024 .
2) Article published within a week.
3) Submit Article : editor@ijmra.in or Online
Why with us
1 : IJMRA only accepts original and high quality research and technical papers.
2 : Paper will publish immediately in current issue after registration.
3 : Authors can download their full papers at any time with digital certificate.
The Editors reserve the right to reject papers without sending them out for review.
Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected. The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.